Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age 18-75 years old, male or female, and signed informed consent form (ICF)~2. Advanced NSCLC diagnosed by pathological or clinical physicians~3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1~4. Participants must have ≥ 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~5. Must be treatment-naive for locally advanced or metastatic squamous NSCLC~6. Life expectancy ≥ 12 weeks~7. Participants must have adequate organ function~8. Male/Female is willing to use a highly effective method of birth control~Key Exclusion Criteria:~1. Diagnosed with NSCLC but with epidermal growth factor receptors (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation~2. Received any approved systemic anticancer therapy~3. Received prior treatment with EGFR inhibitors or ALK inhibitors~4. Received prior therapies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1)~5. With history of interstitial lung disease~6. Clinically significant pericardial effusion~7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis~8. Any major surgical procedure before randomization~9. Human immunodeficiency virus infection~10. Untreated hepatitis B virus (HBV)/hepatitis C virus (HCV)~11. Active autoimmune diseases or history of autoimmune diseases~12. History of allergic reactions to chemotherapy~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tislelizumab + Paclitaxel + Carboplatin (Type: EXPERIMENTAL): Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
- Tislelizumab + Nab-paclitaxel + Carboplatin (Type: EXPERIMENTAL): Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
- Paclitaxel + Carboplatin (Type: ACTIVE_COMPARATOR): Paclitaxel 175 mg/m\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete